^
    Back
    Association details:
    Biomarker:ER negative
    Cancer:HER2 Positive Breast Cancer
    Drug Class:HER2 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Hum Pathol
    Title:

    Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study

    Published date:
    11/17/2023
    Excerpt:
    Similarly, a higher rate of pathologic response (pCR/RCB-I) was observed in H-NCT (7/11, 64 %), followed by NET group (5/9, 56 %), and NCT only group (1/7, 13 %) (p = 0.053)….We conclude that ER-/HER2+ and ER+/HER2-mucinous carcinomas of the breast show robust pathological response to neoadjuvant HER2 targeted and endocrine therapy, respectively. Our findings suggest that MC may show good response to endocrine therapy.
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.1016/j.humpath.2023.10.002